Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2022 Mar 7

PMID 35250311

Authors

Karen M Yun

Lyudmila A Bazhenova

Affiliations

Soon will be listed here.

Abstract

Lorlatinib is an oral third-generation inhibitor of anaplastic lymphoma kinase (ALK) with activity in advanced ALK-positive non-small cell lung cancer (NSCLC) in both the first and subsequent line setting. Superior systemic and intracranial efficacy of lorlatinib over crizotinib, a first-generation ALK tyrosine kinase inhibitor (TKI), in treatment-naïve patients with advanced ALK-positive NSCLC was demonstrated by the phase 3 CROWN trial. Lorlatinib retains anti-tumor effect against single and some compound ALK resistance mutations after disease progression on first- and second-generation ALK TKIs. Currently, alectinib, brigatinib, ceritinib, crizotinib and lorlatinib are approved for treatment of advanced ALK-positive NSCLC. However, no head-to-head studies have directly compared lorlatinib to second-generation ALK inhibitors. Herein, we aim to provide an overview of the efficacy and safety of lorlatinib and discuss where lorlatinib stands in the therapeutic approach to advanced ALK-positive NSCLC.

Citing Articles

A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.

Balasundaram A, Doss G Front Mol Biosci. 2024; 10:1306046.

PMID: 38274094 PMC: 10808363. DOI: 10.3389/fmolb.2023.1306046.

Recent Advances in the Management of Adverse Events Associated with Lorlatinib.

Liao D, Zhang J, Yan T, Chen S, Li W, Shangguan D Onco Targets Ther. 2023; 16:731-738.

PMID: 37694103 PMC: 10492578. DOI: 10.2147/OTT.S426989.

Diverse Neutrophil Functions in Cancer and Promising Neutrophil-Based Cancer Therapies.

Sounbuli K, Mironova N, Alekseeva L Int J Mol Sci. 2022; 23(24).

PMID: 36555469 PMC: 9779721. DOI: 10.3390/ijms232415827.

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.

Verdura S, Encinar J, Fernandez-Arroyo S, Joven J, Cuyas E, Bosch-Barrera J Int J Mol Sci. 2022; 23(17).

PMID: 36077379 PMC: 9456400. DOI: 10.3390/ijms23179986.

References

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Bauer T, Felip E, Solomon B, Thurm H, Peltz G, Chioda M . Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019; 24(8):1103-1110. PMC: 6693708. DOI: 10.1634/theoncologist.2018-0380. View

Camidge D, Kim H, Ahn M, Yang J, Han J, Hochmair M . Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020; 38(31):3592-3603. PMC: 7605398. DOI: 10.1200/JCO.20.00505. View

Du X, Shao Y, Qin H, Tai Y, Gao H . ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018; 9(4):423-430. PMC: 5879058. DOI: 10.1111/1759-7714.12613. View

Nakashima K, Demura Y, Kurokawa K, Takeda T, Jikuya N, Oi M . Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report. Medicine (Baltimore). 2021; 100(39):e27385. PMC: 8483815. DOI: 10.1097/MD.0000000000027385. View

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

Soria J, Tan D, Chiari R, Wu Y, Paz-Ares L, Wolf J . First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017; 389(10072):917-929. DOI: 10.1016/S0140-6736(17)30123-X. View

Peters S, Camidge D, Shaw A, Gadgeel S, Ahn J, Kim D . Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):829-838. DOI: 10.1056/NEJMoa1704795. View

Costa D, Shaw A, Ou S, Solomon B, Riely G, Ahn M . Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015; 33(17):1881-8. PMC: 4451171. DOI: 10.1200/JCO.2014.59.0539. View

10.

Gainor J, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R . Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016; 6(10):1118-1133. PMC: 5050111. DOI: 10.1158/2159-8290.CD-16-0596. View

11.

Zou H, Friboulet L, Kodack D, Engstrom L, Li Q, West M . PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015; 28(1):70-81. PMC: 4504786. DOI: 10.1016/j.ccell.2015.05.010. View

12.

Solomon B, Besse B, Bauer T, Felip E, Soo R, Camidge D . Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018; 19(12):1654-1667. DOI: 10.1016/S1470-2045(18)30649-1. View

13.

Shaw A, Kim T, Crino L, Gridelli C, Kiura K, Liu G . Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017; 18(7):874-886. DOI: 10.1016/S1470-2045(17)30339-X. View

14.

Camidge D, Kim H, Ahn M, Yang J, Han J, Hochmair M . Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021; 16(12):2091-2108. DOI: 10.1016/j.jtho.2021.07.035. View

15.

Felip E, Shaw A, Bearz A, Camidge D, Solomon B, Bauman J . Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021; 32(5):620-630. DOI: 10.1016/j.annonc.2021.02.012. View

16.

Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M . Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021; 7(11):1617-1625. PMC: 8414368. DOI: 10.1001/jamaoncol.2021.3523. View

17.

Dagogo-Jack I, Rooney M, Lin J, Nagy R, Yeap B, Hubbeling H . Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity. Clin Cancer Res. 2019; 25(22):6662-6670. PMC: 6858956. DOI: 10.1158/1078-0432.CCR-19-1436. View

18.

Mok T, Camidge D, Gadgeel S, Rosell R, Dziadziuszko R, Kim D . Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020; 31(8):1056-1064. DOI: 10.1016/j.annonc.2020.04.478. View

19.

Duruisseaux M, Besse B, Cadranel J, Perol M, Mennecier B, Bigay-Game L . Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017; 8(13):21903-21917. PMC: 5400633. DOI: 10.18632/oncotarget.15746. View

20.

Yoda S, Lin J, Lawrence M, Burke B, Friboulet L, Langenbucher A . Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018; 8(6):714-729. PMC: 5984716. DOI: 10.1158/2159-8290.CD-17-1256. View